DanCann Pharma A/S announced that Magnus Østergaard Dahlmann has chosen to transfer the position of Chairman of the Board of Directors of the biopharmaceutical company DanCann Pharma A/S to Carsten Trads due to health reasons. Magnus Østergaard Dahlmann will continue as a member of the company's Board of Directors. The change of chairmanship is quite undramatic and is due to a desire from Magnus Østergaard Dahlmann to disengage resources in connection with a long-term course of treatment, and subsequently the Board of Directors has chosen to distribute the tasks differently.